Henrik Lundin

Biotome develops antibody tests using next generation technology and precision immunology to address the problems of traditional serology tests. Our antibody tests surpass current antibody screening with enhanced precision and more detailed disease information. We use an efficient, scalable process of discovering precision markers for diagnosis, applicable to any disease that triggers an immune response. The patentable peptide markers are fundamental to our commercialization process. IP protection carves out space for our precision diagnostics in a market dominated by lower-accuracy, non-proprietary tests from huge corporations. Biotome also offers cutting-edge expertise in marker identification, patenting, and precision immunology data analytics to research companies and organizations.